Pharmacy and Therapeutics Committee Meeting Review Schedules

SFY2025 Updated 5/16/2024

| Meeting #91 | Meeting #92 | Meeting #93 | Meeting #94 |
|---|--|--|---|
| September 20, 2024 | November 15, 2024 | January 17, 2025 | April 18, 2025 |
| Clinical Submission Deadline: 9/6/2024 | Clinical Submission Deadline: 11/1/2024 | Clinical Submission Deadline: 1/3/2025 | Clinical Submission Deadline: 4/4/2025 |
| GASTROINTESTINAL | CENTRAL NERVOUS SYSTEM | RESPIRATORY/ALLERGY | CARDIOVASCULAR |
| Antiemetic – Antivertigo Agents | Alzheimer's Agents | Antihistamines, Minimally Sedating | ACE-Inhibitors & Renin Inhibitors |
| Cytokine & CAM Antagonist, GI | Anticonvulsants | Beta-agonist Bronchodilators, Long | Angiotensin Receptor Blockers (ARB) |
| Irritable Bowel Syndrome & GI Motility | Antidepressants | Beta-agonist Bronchodilators, Short | Angiotensin Modulator/CCB Combo |
| Proton Pump Inhibitors | Antipsychotics – Atypical | COPD Agents | Antianginal and Anti-Ischemic |
| Ulcerative Colitis | Multiple Sclerosis Agents | Epinephrine, Self-Injected | Anticoagulants |
| ENDOCRINE/METABOLIC | Sedative Hypnotics | Glucocorticoids, Inhaled, Single-entity | Erythropoiesis Stimulating Agents |
| Hypoglycemics / Incretin Mimetic- Enhancer | Stimulants & Related Agents | Glucocorticoids, Inhaled, Combination | Lipotropics, Other |
| Hypoglycemics / Metformin | SUBSTANCE DEPENDENCE | Intranasal Rhinitis Agents | PCSK-9 Inhibitors |
| Hypoglycemics / SGLT2 | Opioid Dependence | Leukotriene Modifiers | Platelet Aggregation Inhibitors |
| Insulin | Opioid Reversal Agents | Immunomodulators, Asthma | Pulmonary Arterial Hypertension (PAH) |
| Glucagon Agents | Smoking Cessation Products | DERMATOLOGICAL | GENITOURINARY |
| Androgenic Agents, Topical | ANALGESICS | Acne, Topical | Benign Prostatic Hyperplasia (BPH) Agents |
| Antihyperuricemics | Antimigraine Agents | Antipsoriatics, Topical | Bladder Relaxant Preparations |
| Urea Cycle Disorders, Oral | Analgesics, Opioid Long-acting | Immunomodulators, Atopic Dermatitis | Vaginal Antibiotics |
| Bone Resorption Inhibitors | Analgesics, Opioid Short-acting | Topical Steroids – Low, Medium, High, Very High Potency | ANTI-INFECTIVE |
| Growth Hormone | Neuropathic Pain | IMMUNOLOGICAL, MIXED | Antifungals, Oral |
| Phosphate Binders | NSAIDS | Cytokine & CAM Antagonist, Other | Antifungals, Topical |
| Progestins for Cachexia | Restless Leg Syndrome (RLS) | Immunosuppressants, Oral | Antivirals, Influenza |
| ANTIRETROVIRALS | Skeletal Muscle Relaxants | OPHTHALMICS | Hepatitis B Agents |
| HIV / AIDS | CYSTIC FIBROSIS | Ophth, Allergic Conjunctivitis | Hepatitis C Agents |
| SINGLE CLASS REVIEW | Antibiotics, Inhaled | Ophth, Antibiotics | Otic Antibiotics |
| Movement Disorders | CFTR Potentiator Agents | Ophth, Antibiotic-Steroid Combo | SINGLE CLASS REVIEW |
| Continuous Glucose Monitors | Pancreatic Enzymes | Ophth, Anti-inflammatory | Hereditary Angioedema |
| | ANTIVIRAL MONOCLONAL ANTIBODIES | Ophth, Glaucoma Agents | Hemophilia |
| | RSV | Ophth, Immunomodulators | |

Drug class listings are based on the anticipated review schedule for the identified dates but are subject to change. Please refer to the official meeting agenda publicly noticed 30 days in advance of the meeting for the final agenda. <u>https://aws.state.ak.us/OnlinePublicNotices/default.aspx</u>